is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.

Technology Services

Our technology service solutions assist you in advancing workflow efficiency, and guide you to full EHR integration to get the connectivity and automation you need.

Technology Solutions

  • PathConnectDermatologyGastroenterolgyUrologyHematologyBreastTechnologyMeaningful Use
    Save hours of valuable time each day by automating your pathology process.
  • gMedConnectGastroenterolgyTechnologyMeaningful Use
    gMedConnect is the leading platform for Gl practices—the only fully integrated, cloud-based system, offering an EMR, electronic report writer, practice management system, and patient portal.
  • Modernizing Medicine EMA DermatologyDermatologyTechnologyMeaningful Use
    Inform Diagnostics’ powerful EMR integration enables practices to improve workflow, save time and focus on patient care.
  • ProVation MDGastroenterolgyTechnology
    ProVation MD is the leading endoscopy report writer for Gl practices. Its dedicated software solutions provide exclusive and extensive high-quality medical content that improve your quality, communication, and efficiency.

Consulting — Inform Diagnostics partners with physician practices to guide you through the complexities of Meaningful Use, Quality Reporting, lCD-10 compliance and more.

Implementation Services — You don't need to be an expert in IT when you partner with Inform Diagnostics. Our expert team is deployed to your practice during and after installation to help prepare your staff, and we provide a personalized training program and project management.

Partners — Inform Diagnostics Life Sciences has chosen industry leaders that provide the most valuable and customized services that are best suited to meet the needs of your practice.

Contact Inform Diagnostics to learn how Inform Diagnostics can assist your practice
Call 1.866.588.3280 or email MiracaTechnology@MiracaLS.com

What You Need,
When You Need It


“The patient info is well written and understandable. Although we have lots of information, finding it when you need it is the problem. Having it with the pathology report helps.”

– Kevin Heath, MD

Learn More »

Miraca’s pathologists have been equally diligent with regard to tailoring their reports to the specifications of each of our physicians. They return reports in a timely fashion, communicate their concerns quickly and have excellent provider support.
— Martha J. Maso, MD, MPH,
Dermatologist, Westwood Dermatology Group, Westwood, N.J.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


January 8, 2018

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help […]

Continue reading


November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading


October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading


October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading


September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading